Stock listing
Frankfurt:1IJ Adicet Bio, Inc. Aktie
German listing (Frankfurt) of Adicet Bio, Inc. · home listing NASDAQ:ACET
Follow Adicet Bio, Inc. into a list and get an email when it puts out news.
Share price · FWB:1IJ
€1.89 EUR -0.29 (-13.3%)
Close on Nov 20, 2026
- Day range
- €1.89 – €1.93 EURNov 20, 2026
- Market cap
- €17.69M EURAt the close on Nov 20, 2026 · price × 9.36M shares outstanding
- 52-week range
- €1.89 – €9.39 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3,766 EURMedian day 80 shares · 27 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACET · Home | $2.14 USD | -0.36 (-14.4%) | 760,371 | $2.43 | $2.53 | $2.12 | $2.50 | Close on Nov 20, 2026 |
| LSE:0HX7 | $2.23 USD | -0.325 (-12.7%) | 390 | $2.43 | $2.50 | $2.23 | $2.555 | Close on Nov 20, 2026 |
| Frankfurt:1IJ | €1.89 EUR | -0.29 (-13.3%) | — | €1.93 | €1.93 | €1.89 | €2.18 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:1IJ · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €2.679 | +0.144 | +5.7% | €2.315 | €2.697 | €2.31 | 0 | |
| €2.535 | -0.092 | -3.5% | €2.477 | €2.556 | €2.45 | 500 | |
| €2.627 | -0.079 | -2.9% | €2.524 | €2.722 | €2.511 | 4,606 | |
| €2.706 | -0.162 | -5.6% | €2.557 | €2.712 | €2.532 | 0 | |
| €2.868 | -0.031 | -1.1% | €2.994 | €3.009 | €2.866 | 0 | |
| €2.899 | -0.197 | -6.4% | €2.899 | €2.899 | €2.899 | 2,946 | |
| €3.096 | +0.005 | +0.2% | €3.116 | €3.312 | €3.059 | 1,674 | |
| €3.091 | -0.22 | -6.6% | €3.091 | €3.091 | €3.091 | 800 | |
| €3.311 | -0.022 | -0.7% | €3.227 | €3.585 | €3.214 | 300 | |
| €3.333 | -0.138 | -4.0% | €3.127 | €3.347 | €3.114 | 300 | |
| €3.471 | -0.18 | -4.9% | €3.471 | €3.471 | €3.471 | 1,700 | |
| €3.651 | -0.308 | -7.8% | €3.651 | €3.651 | €3.651 | 0 | |
| €3.959 | -0.007 | -0.2% | €3.753 | €3.966 | €3.686 | 0 | |
| €3.966 | +0.073 | +1.9% | €3.757 | €4.014 | €3.754 | 0 | |
| €3.893 | -0.312 | -7.4% | €3.804 | €3.91 | €3.794 | 0 | |
| €4.205 | -0.153 | -3.5% | €4.205 | €4.205 | €4.205 | 0 | |
| €4.358 | +0.099 | +2.3% | €3.951 | €4.424 | €3.936 | 0 | |
| €4.259 | -0.417 | -8.9% | €4.259 | €4.259 | €4.259 | 0 | |
| €4.676 | -0.052 | -1.1% | €4.676 | €4.676 | €4.676 | 0 | |
| €4.728 | -0.098 | -2.0% | €4.728 | €4.728 | €4.728 | 0 | |
| €4.826 | -0.112 | -2.3% | €4.826 | €4.826 | €4.826 | 3,888 | |
| €4.938 | -0.478 | -8.8% | €5.149 | €5.154 | €4.895 | 400 | |
| €5.416 | -0.089 | -1.6% | €5.297 | €5.42 | €5.292 | 0 | |
| €5.505 | -0.30 | -5.2% | €5.50 | €5.506 | €5.498 | 0 | |
| €5.805 | +0.105 | +1.8% | €5.517 | €5.814 | €5.445 | 100 | |
| €5.70 | -0.207 | -3.5% | €5.597 | €5.932 | €5.583 | 534 | |
| €5.907 | -0.42 | -6.6% | €6.046 | €6.082 | €5.89 | 0 | |
| €6.327 | +0.952 | +17.7% | €5.762 | €6.356 | €5.705 | 200 | |
| €5.375 | -0.979 | -15.4% | €5.376 | €5.376 | €5.316 | 250 | |
| €6.354 | -1.025 | -13.9% | €8.082 | €9.39 | €6.307 | 2,633 | |
| €7.379 | +0.32 | +4.5% | €6.948 | €7.467 | €6.893 | 424 | |
| €7.059 | -0.403 | -5.4% | €7.24 | €7.405 | €7.004 | 369 | |
| €7.462 | -0.516 | -6.5% | €7.674 | €7.702 | €7.445 | 1,280 | |
| €7.978 | +0.285 | +3.7% | €7.656 | €7.979 | €7.644 | 0 | |
| €7.693 | -0.079 | -1.0% | €7.706 | €7.713 | €7.659 | 0 | |
| €7.772 | +0.121 | +1.6% | €7.61 | €7.851 | €7.599 | 80 | |
| €7.651 | +0.389 | +5.4% | €7.651 | €7.651 | €7.651 | 0 | |
| €7.262 | -0.852 | -10.5% | €7.016 | €7.337 | €6.993 | 400 | |
| €8.114 | -0.047 | -0.6% | €8.114 | €8.114 | €8.114 | 0 | |
| €8.161 | +0.201 | +2.5% | €7.876 | €8.179 | €7.855 | 69 | |
| €7.96 | +0.086 | +1.1% | €7.96 | €7.96 | €7.96 | 2,080 | |
| €7.874 | -0.154 | -1.9% | €7.874 | €7.874 | €7.874 | 0 | |
| €8.028 | -0.077 | -1.0% | €8.018 | €8.065 | €7.997 | 941 | |
| €8.105 | +0.247 | +3.1% | €7.928 | €8.144 | €7.906 | 0 | |
| €7.858 | +0.086 | +1.1% | €7.858 | €7.858 | €7.858 | 0 | |
| €7.772 | +0.123 | +1.6% | €7.772 | €7.772 | €7.772 | 3,209 | |
| €7.649 | -0.065 | -0.8% | €7.649 | €7.649 | €7.649 | 0 | |
| €7.714 | -0.256 | -3.2% | €7.714 | €7.714 | €7.714 | 0 | |
| €7.97 | +0.508 | +6.8% | €7.322 | €8.01 | €7.271 | 100 | |
| €7.462 | -0.301 | -3.9% | €7.462 | €7.462 | €7.462 | 3,209 | |
| €7.763 | +0.433 | +5.9% | €7.763 | €7.763 | €7.763 | 3,209 | |
| €7.33 | -0.568 | -7.2% | €7.33 | €7.33 | €7.33 | 0 | |
| €7.898 | +0.668 | +9.2% | €7.44 | €7.938 | €7.43 | 200 | |
| €7.23 | -0.599 | -7.7% | €7.23 | €7.23 | €7.23 | 0 | |
| €7.829 | -0.025 | -0.3% | €7.829 | €7.829 | €7.829 | 759 | |
| €7.854 | +0.067 | +0.9% | €7.738 | €7.922 | €7.659 | 1,006 | |
| €7.787 | +0.272 | +3.6% | €7.787 | €7.787 | €7.787 | 0 |
Splits
1 split · FWB:1IJ · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-16 | Consolidation |
- Ticker
- Frankfurt:1IJ
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 30, 2026
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Latest deck · Sep 28, 2026
Technical Presentation (September 2026)
Technical · 30 slides
Latest news
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Oct 30, 2026
Closed €2.87 (-1.1%) on Nov 2, 2026
Adicet Bio to Participate in Upcoming Investor Conferences
Oct 22, 2026
Closed €3.47 (-4.9%) on Oct 23, 2026
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Sep 28, 2026
Closed €6.35 (-13.9%) on Sep 28, 2026
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Sep 25, 2026
Closed €6.35 (-13.9%) on Sep 28, 2026
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
Sep 1, 2026
Closed €7.97 (+6.8%) on Sep 1, 2026
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
Aug 27, 2026
Closed €7.76 (+5.9%) on Aug 28, 2026
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 5, 2026
Closed €6.56 (-20.7%) on Aug 6, 2026
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
Jul 21, 2026
Closed €7.23 (+6.8%) on Jul 22, 2026
Amendment to Annual Report (Form 10-K/A)
May 20, 2026
Closed €6.29 (+5.5%) on May 21, 2026
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 14, 2026
Closed €6.93 (+5.9%) on May 15, 2026
Adicet Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 38 in all · newest Oct 30, 2026 · oldest 2020
- Decks
- 24 decks · latest Sep 28, 2026
Where Adicet Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACET · Home listing | NASDAQ | United States | USD |
| LS Exchange:A41X5V | LS Exchange | Germany | EUR |
| BOATS:ACET | BOATS | United States | USD |
| Lang & Schwarz:A41X5V | Lang & Schwarz | Germany | EUR |
| LSE:0HX7 | LSE | United Kingdom | USD |
| Dusseldorf:1IJ | Dusseldorf | Germany | EUR |
| Frankfurt:1IJ · This page | Frankfurt | Germany | EUR |
| gettex:1IJ | gettex | Germany | EUR |
| Munich:1IJ | Munich | Germany | EUR |
| Tradegate:1IJ | Tradegate | Germany | EUR |
Valuation
Price/book 0.2× against a median of 1.2×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.02M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 2.02
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Adicet Bio, Inc. · NASDAQ:ACET | US$20.03M | US$5.02M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 2.02 |
| ZYUS Life Sciences Corporation · TSXV:ZYUS | US$20.92M | US$25.65M | n/a | 98.4× | n/a | n/a | n/a | n/a | -0.02 |
| Xbrane Biopharma AB · OMXSTO:XBRANE | US$20.88M | US$23.48M | n/a | 1.9× | n/a | 0.4× | −49.0% | 0.1× | n/a |
| Vivoryon Therapeutics N.V. · EURONEXT:VVY | US$20.48M | US$17.77M | n/a | n/a | n/a | 11.9× | n/a | 0.1× | n/a |
| Evaxion A/S · NASDAQ:EVAX | US$20.30M | US$13.40M | n/a | 1.8× | n/a | 2.1× | −115.1% | 0.8× | 0.78 |
| Aardvark Therapeutics, Inc. · NASDAQ:AARD | US$20.20M | −US$39.58M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 3.28 |
| GenSight Biologics SA · EURONEXT:SIGHT | US$20.19M | US$32.44M | n/a | 29,573× | n/a | n/a | n/a | n/a | n/a |
| TransCode Therapeutics, Inc. · NASDAQ:RNAZ | US$20.07M | US$15.44M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.03 |
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| Provectus Biopharmaceuticals, Inc. · OTC:PVCT | US$19.12M | US$18.94M | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| LeonaBio, Inc. · NASDAQ:LONA | US$19.03M | −US$12.82M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.04 |
| Median of the others | US$20.19M | US$18.35M | 50.1× | 1.2× | −82.1% | 0.0× | 1.03 |
Forecasts
6 strong buy · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 29.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -7.36 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Chen Schor | Director, President and Chief Executive Officer |
| Lloyd Klickstein | Interim Chief Medical Officer/ Board of Directors |
Board
| Director | Role |
|---|---|
| Andrew Sinclair | Lead Director |
| Chen Schor | Director, President and Chief Executive Officer |
| Jeffrey A. Chodakewitz | Director |
| Lloyd Klickstein | Interim Chief Medical Officer/ Board of Directors |
| Michael Grissinger | Director |
| Steve Dubin | Member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +4.5% |
| Q2 2026 | Aug 5, 2026 · After close | −13.4% |
| Q1 2026 | May 13, 2026 · After close | +4.2% |
| Q4 2025 | Mar 5, 2026 | −3.7% |
| Q3 2025 | Nov 5, 2025 · After close | −1.9% |
| Q2 2025 | Aug 7, 2025 · After close | −9.6% |
| Q1 2025 | May 6, 2025 · After close | −18.6% |
| Q4 2024 | Mar 17, 2025 · Before open | −0.7% |
| Q3 2024 | Nov 6, 2024 · After close | +2.3% |
| Q2 2024 | Aug 13, 2024 · Before open | +2.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +5.3% |
| Q4 2023 | Mar 19, 2024 · After close | +5.4% |
| Q3 2023 | Nov 8, 2023 · After close | −6.0% |
| Q2 2023 | Aug 9, 2023 · After close | +11.9% |
| Q1 2023 | May 9, 2023 · After close | +3.0% |
| Q4 2022 | Mar 15, 2023 · After close | 0.0% |
| Q3 2022 | Nov 8, 2022 · After close | +1.2% |
| Q2 2022 | Aug 10, 2022 · Before open | −3.8% |
| Q1 2022 | May 12, 2022 · After close | +11.3% |
| Q4 2021 | Mar 15, 2022 · After close | +22.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2026) | Technical | 30 slides | Sep 28, 2026 |
| Investor Presentation (September 2026) | Investor deck | 34 slides | Sep 8, 2026 |
| Corporate Update (October 2025) | Corporate update | 31 slides | Oct 7, 2025 |
| 27th ASGCT Annual Meeting 2024 | Conference | 16 slides | May 10, 2024 |
| Investor Presentation (January 2024) | Investor deck | 37 slides | Jan 16, 2024 |
| 27th ASGCT Annual Meeting 2024 | Conference | 16 slides | 2024 |
| American College of Rheumatology (ACR) Annual Meeting 2024 | Conference | 15 slides | 2024 |
| Technical Presentation (November 2022) | Technical | 53 slides | Nov 10, 2022 |
| Merger or Acquisition (September 2020) | Merger or acquisition | 34 slides | Sep 16, 2020 |
| resTORbio — Merger or Acquisition (July 2020) | Merger or acquisition | 39 slides | Jul 28, 2020 |
All 24 decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock and pre-funded warrants Announced: about US$80M · US$1 a share · Jefferies +4 Dealers: Jefferies (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead), Wedbush PacGrow, H.C. Wainwright & Co. | Oct 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as resTORbio, Inc. Priced at US$15.00 a share on Jan 25, 2018.
- Price
- US$15.00 a share
- Shares offered
- 5,666,667 shares of common stock
- Offering size
- US$85 million
- Underwriters' option
- Up to 850,000 more shares
- Underwriters
- BofA Merrill Lynch, Leerink Partners, Evercore ISI, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Jan 30, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 27, 2017 |
| Filed publicly | Dec 29, 2017 |
| Amended once | Jan 16, 2018 |
| Shares registered with an exchange | Jan 22, 2018 |
| Declared effective by the SEC | Jan 25, 2018 |
| Final prospectus, with the price | Jan 29, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 29, 2018 |
| CERT · Exchange's certificate of listing | Jan 25, 2018 |
| EFFECT · Notice that a registration is effective | Jan 25, 2018 |
| CORRESP · Letter to the SEC | Jan 23, 2018 |
| CORRESP · Letter to the SEC | Jan 23, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 22, 2018 |
| S-1/A · Registration statement, amended | Jan 16, 2018 |
| CORRESP · Letter to the SEC | Jan 5, 2018 |
| S-1 · Registration statement | Dec 29, 2017 |
| DRSLTR · Letter to the SEC with a draft | Dec 22, 2017 |
All 16 filings
| Filing | Filed |
|---|---|
| DRS/A · Draft registration statement, amended | Dec 22, 2017 |
| UPLOAD · Letter from the SEC | Dec 18, 2017 |
| DRSLTR · Letter to the SEC with a draft | Dec 1, 2017 |
| DRS/A · Draft registration statement, amended | Dec 1, 2017 |
| UPLOAD · Letter from the SEC | Nov 22, 2017 |
| DRS · Draft registration statement | Oct 27, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 29, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 25.0M | 9.73M | 17.9M | 995.0K | 8.18M | 558.5M | 547.0M |
| Cost of revenue | 6.38M | 6.47M | 6.10M | 5.01M | 125.0K | 80.0K | 5.00K | 411.5M | ||
| Gross profit | -6.38M | -6.47M | -6.10M | 25.0M | 9.73M | 17.9M | 995.0K | 8.10M | 558.5M | 135.4M |
| Research and development | 99.1M | 99.3M | 106.0M | 71.2M | 48.9M | 34.3M | 23.7M | 14.7M | 16.8M | 5.94M |
| Selling, general and administrative | 23.0M | 28.3M | 26.5M | 26.3M | 22.2M | 22.8M | 8.69M | 8.43M | 76.8M | 73.2M |
| Operating income | -122.1M | -127.6M | -152.0M | -72.6M | -61.4M | -39.2M | -31.4M | -15.0M | -18.9M | -1.00K |
| Depreciation and amortization | 6.38M | 6.47M | 6.10M | 2.58M | 1.54M | 1.23M | 1.24M | 1.22M | 5.00K | 11.8M |
| EBITDA | -115.7M | -121.1M | -145.9M | -70.0M | -59.9M | -38.0M | -30.1M | -13.7M | -18.9M | 11.8M |
| Interest expense | 36.0K | 4.00K | 25.0K | 80.0K | 176.0K | 134.0K | 7.00M | 3.95M | ||
| Income before tax | -116.8M | -117.1M | -142.7M | -69.8M | -62.1M | -39.5M | -28.1M | -9.89M | -33.8M | -1.00K |
| Income tax | 0 | 0 | 0 | 0 | -125.0K | -2.81M | 19.0K | -589.0K | 0 | 20.4M |
| Net income | -116.8M | -117.1M | -142.7M | -69.8M | -62.0M | -36.7M | -28.1M | -9.30M | -33.8M | -1.00K |
| Earnings per share, basic | -16.95 | -21.33 | -3.31 | -1.70 | -2.00 | -5.01 | -13.15 | -4.78 | -8.42 | -0.00 |
| Earnings per share, diluted | -16.95 | -21.33 | -3.31 | -1.70 | -2.00 | -5.01 | -13.15 | -4.78 | -8.42 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 38.9M | 56.5M | 159.7M | 257.7M | 277.5M | 84.3M | 10.6M | 9.47M | 53.3M | 66.8M |
| Short-term investments | 119.6M | 119.8M | 0 | 0 | 10.3M | 51.8M | 101.0M | 0 | 881.0K | |
| Receivables | 342.0K | 435.0K | 214.0K | 2.73M | 935.0K | 260.9M | 167.6M | |||
| Inventory | 2.57M | 4.68M | -3.09M | 672.0K | 136.4M | 98.1M | ||||
| Current assets | 160.9M | 180.1M | 162.3M | 261.0M | 282.4M | 100.3M | 64.2M | 109.5M | 55.2M | 352.7M |
| Property, plant and equipment | 16.5M | 22.5M | 26.8M | 28.7M | 14.6M | 2.79M | 2.12M | 321.0K | 39.0K | |
| Goodwill | 0 | 19.5M | 19.5M | 20.1M | 237.0M | 67.9M | ||||
| Total assets | 192.4M | 220.2M | 207.3M | 330.7M | 338.9M | 153.8M | 81.6M | 109.9M | 55.2M | 540.8M |
| Accounts payable | 4.74M | 4.83M | 2.63M | 4.40M | 3.26M | 1.55M | 1.05M | 2.99M | 1.51M | 46.0M |
| Current liabilities | 21.5M | 19.4M | 19.3M | 19.7M | 16.3M | 22.5M | 14.9M | 5.72M | 5.50M | 98.9M |
| Total debt | 14.7M | 17.2M | 20.9M | 21.0M | 20.9M | 21.6M | 114.1M | 3.11M | 353.7M | 118.8M |
| Total liabilities | 33.1M | 33.6M | 37.1M | 38.4M | 35.8M | 44.0M | 27.9M | 5.74M | 5.50M | 236.3M |
| Shareholders' equity | 159.2M | 186.6M | 170.2M | 292.3M | 303.1M | 109.8M | -60.4M | -33.5M | -26.9M | 304.4M |
| Shares outstanding | 9.59M | 5.16M | 43.3M | 43.0M | 39.7M | 39.7M | 2.16M | 28.1M | 5.66M | 1.75M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -95.2M | -92.4M | -93.7M | -44.8M | -51.1M | -41.6M | -27.9M | -18.2M | -11.0M | 8.34M |
| Capital spending | -1.74M | -1.12M | -4.46M | -16.8M | -13.0M | -990.0K | -1.07M | -876.0K | -44.0K | -617.0K |
| Free cash flow | -97.0M | -93.5M | -98.2M | -61.5M | -64.1M | -42.5M | -29.0M | -19.1M | -11.0M | 7.73M |
| Cash from investing | 2.39M | -119.2M | -4.46M | -16.8M | -2.80M | 115.2M | -47.9M | -16.1M | -44.0K | -8.97M |
| Cash from financing | 75.2M | 111.3M | 236.0K | 41.5M | 242.7M | 303.0K | 76.9M | 11.0M | 64.4M | -8.24M |
| Dividends paid | -7.08M | -6.96M | ||||||||
| Share buybacks | -150.0K | -3.23M | -55.7M | -66.8M | ||||||
| Change in cash | -17.6M | -100.3M | -97.9M | -20.0M | 188.8M | 74.0M | 1.13M | -23.2M | 53.3M | -8.88M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 10-K/A · Annual report, amended | May 20, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| S-8 POS | May 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2026 | Financing | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 13, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 24, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 19, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 18, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| S-3 · Registration statement | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 8-K · Current report | Dec 29, 2025 | Current report | SEC |
| 8-K · Current report | Dec 19, 2025 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Nov 17, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Nov 5, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2025 | Current report | SEC |
| 8-K · Current report | Oct 7, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 7, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Jul 25, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 17, 2025 | Management or board change | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| S-8 POS | Mar 26, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Mar 18, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 12, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 11, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2025 | Offer document | SEC |
| S-3 · Registration statement | Mar 6, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| 8-K · Current report | Feb 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2024 | Current report | SEC |
| 8-K · Current report | Nov 27, 2024 | Current report | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| 8-K · Current report | Nov 15, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 8-K · Current report | Oct 16, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 8-K · Current report | Sep 19, 2024 | Current report | SEC |
| 8-K · Current report | Sep 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 19, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 8, 2024 | Current report | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jun 5, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 5, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 8-K · Current report | May 10, 2024 | Current report | SEC |
| DEFR14A | Apr 26, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 22, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 22, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Mar 22, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 21, 2024 | Big-stake notice | SEC |
| S-8 POS | Mar 19, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 27, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 5, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 2, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 31, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 24, 2024 | Results | SEC |
| 424B5 · Prospectus | Jan 24, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 23, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jan 22, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Jan 19, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 16, 2024 | Current report | SEC |
| 8-K · Current report | Jan 4, 2024 | Current report | SEC |
| 8-K · Current report | Nov 13, 2023 | Management or board change | SEC |
This page holds 200 of 683 filings. Open Filings
Cap table
Built by 6ix from Adicet Bio, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 9,361,596
- Fully diluted
- 9,361,596
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 9,361,596 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 9,361,596 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carl Gordon Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past) | Director · Sep 15, 2020 – Aug 21, 2024 · Past |
| Erez Chimovits Other companies: ADARx Pharmaceuticals, Inc. (Partner at OrbiMed Advisors · Since at least Sep 24, 2026); Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); BiomX Inc. (Director · Oct 28, 2019 – Mar 25, 2020 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Oct 1, 2020 · Past); Eledon Pharmaceuticals, Inc. (Director · May 10, 2017 – Jan 14, 2020 · Past) | Director · Sep 15, 2020 – Jun 27, 2023 · Past |
| Michael Kauffman Other companies: Kyntra Bio, Inc. (Director · Since at least Jun 4, 2025); Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Verastem, Inc. (President, Development · Since at least Nov 26, 2012); Karyopharm Therapeutics Inc. (Director · Nov 5, 2013 – Feb 28, 2022 · Past); EPIRUS Biopharmaceuticals Inc (Director · Jan 15, 2010 – Jun 6, 2013 · Past); Onyx Pharmaceuticals Inc (Chief Medical Officer · Nov 16, 2009 – Feb 9, 2010 · Past) | Director · Nov 17, 2021 – Aug 21, 2024 · Past |
| Paul Fonteyne Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); Amylyx Pharmaceuticals, Inc. (Director · Since at least Jan 6, 2022); Apellis Pharmaceuticals, Inc. (Director · Since at least Apr 2, 2020); Covetrus Inc (Director · Jul 1, 2021 – Oct 13, 2022 · Past); AMAG Pharmaceuticals Inc (Director · Oct 8, 2019 – Nov 16, 2020 · Past) | Director · Jan 25, 2018 – Jun 3, 2020 · Past |
| Jeffrey A Chodakewitz Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Apr 13, 2021); Schrodinger, Inc. (Board Member · Since at least Apr 30, 2020); Vertex Pharmaceuticals Incorporated (EVP · Jul 15, 2014 – Apr 1, 2018 · Past); Tetraphase Pharmaceuticals Inc (Director · Jun 12, 2014 – Jun 10, 2019 · Past) | Director · Since at least Aug 14, 2018 |
| Jonathan Silverstein Other companies: Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Oct 2, 2020 · Past); Glaukos Corporation (Director · Dec 13, 2017 – Mar 2, 2018 · Past); Scpharmaceuticals Inc (Director · Nov 16, 2017 – Nov 21, 2017 · Past); Rhythm Pharmaceuticals, Inc. (Director · Oct 4, 2017 – Oct 4, 2017 · Past) | Director · Jan 25, 2018 – Jun 3, 2020 · Past |
| Lynne Sullivan Other companies: Inozyme Pharma Inc (Director · Since at least Jul 23, 2020); Solid Biosciences Inc. (Chief Financial Officer at Unity Biotechnology · Since at least Jan 25, 2018); Unity Biotechnology Inc (CFO & Head of Corp. Dev. · Aug 1, 2020 – Apr 2, 2025 · Past); BiomX Inc. (Director · Nov 4, 2019 – Mar 1, 2023 · Past) | Director · Jan 25, 2018 – Jun 3, 2020 · Past |
| Andrew Sinclair Other companies: Soleno Therapeutics, Inc. (Director · Since at least Dec 21, 2018); Verona Pharma plc (Director · Jan 1, 2021 – Aug 9, 2021 · Past); Sierra Oncology Inc (Director · Nov 22, 2019 – Jul 1, 2022 · Past) | Lead Director · Since at least Mar 2, 2021 |
| Chen Schor Other companies: Karyopharm Therapeutics Inc. (Director · Since at least Nov 25, 2020); Madrigal Pharmaceuticals, Inc. (Former President and CEO, Director · Dec 8, 2014 – Jul 22, 2016 · Past); Brainstorm Cell Therapeutics Inc. (Director · Aug 22, 2011 – Nov 30, 2018 · Past) | Director, President and Chief Executive Officer · Since at least Jan 25, 2018 |
| Michael Grissinger Other companies: Lipocine Inc. (Director · Since at least Aug 3, 2026); Aprea Therapeutics, Inc. (Director · Since at least May 16, 2022); Akari Therapeutics PLC (Director · Jan 1, 2024 – Jun 28, 2024 · Past) | Director · Since at least Nov 5, 2018 |
All 27 people
| Person | Seat |
|---|---|
| Stewart Abbot Other companies: Turnstone Biologics Corp. (Chief Scientific Officer · Jul 20, 2023 – Oct 16, 2023 · Past); Fate Therapeutics, Inc. (Chief Development Officer · Oct 6, 2015 – May 15, 2018 · Past) | See Remarks · Sep 15, 2020 – Jun 11, 2021 · Past |
| Brian Nicholas Harvey Other companies: Radius Health, Inc. (Sr. VP and CFO · Feb 10, 2016 – Apr 25, 2017 · Past) | Chief Financial Officer · Since at least Sep 15, 2020 |
| Carrie Krehlik Other companies: Global Blood Therapeutics Inc (Chief Human Resources Officer · Aug 2, 2021 – Oct 5, 2022 · Past) | Chief Human Resources Officer · Sep 15, 2020 – Feb 12, 2021 · Past |
| Daphne Zohar Other companies: Seaport Therapeutics, Inc. (Founder, CEO & Board Member · Since at least Apr 30, 2026) | Director · Jan 25, 2018 – Jan 25, 2018 · Past |
| Don Healey Other companies: Acer Therapeutics Inc (Chief Scientific Officer · Oct 26, 2015 – May 16, 2016 · Past) | Chief Technology Officer · Since at least Oct 26, 2020 |
| John J McCabe Other companies: Eleven Biotherapeutics Inc (Chief Financial Officer · Jul 3, 2015 – Apr 3, 2017 · Past) | Vice President, Finance · Jan 25, 2018 – Dec 6, 2019 · Past |
| Meredith Manning Other companies: Soleno Therapeutics, Inc. (Chief Commercial Officer · Since at least Apr 22, 2024) | Chief Commercial Officer · Sep 17, 2018 – Feb 27, 2019 · Past |
| Steve Dubin Other companies: Martek Biosciences Corp (Chief Executive Officer, Director · Jul 7, 2010 – Feb 25, 2011 · Past) | Director · Since at least Sep 15, 2020 |
| Aya Jakobovits | Director · Sep 15, 2020 – Aug 21, 2024 · Past |
| Blake Aftab | Chief Scientific Officer · Since at least Oct 12, 2021 |
| David Adam Steinberg | Director · Jan 25, 2018 – Jun 3, 2020 · Past |
| Francesco Galimi | SVP & Chief Medical Officer · Sep 15, 2020 – Jun 5, 2024 · Past |
| Joan Mannick | Chief Medical Officer · Jan 25, 2018 – Dec 6, 2019 · Past |
| Julia D Maltzman | Chief Medical Officer · Since at least Jan 13, 2025 |
| Lloyd Klickstein | Interim Chief Medical Officer/ Board of Directors · Since at least May 13, 2019 |
| Steve Dubin | Member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee · Since at least Nov 4, 2026 |
| Yair Chaim Schindel | Director · Sep 15, 2020 – Sep 15, 2020 · Past |
Log in to ask 6ix AI your own questions about Adicet Bio, Inc.